New insulin treatment for diabetics who can't sense low blood sugar
Official title: Dual Agonist Insulins for Treating Diabetics with Impaired Awareness ofHypoglycemia (IAH)
Funded at Amidebio, LLC · NIH-11007128 · Data updated 2026-11-12
This study is testing a new insulin treatment for adults with diabetes who have trouble sensing low blood sugar, hoping to help them manage their condition better and avoid dangerous lows.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Amidebio, LLC NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $929,940 |
| NIH project number | 1R44DK141357-01 |
| Project ID | NIH-11007128 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults with diabetes who have impaired awareness of hypoglycemia.
✕Less likely to help
Patients who do not have diabetes or those who do not experience impaired awareness of hypoglycemia may not benefit from this research.
What this research studies
This research focuses on developing a new type of insulin treatment designed specifically for adults with diabetes who experience impaired awareness of hypoglycemia (IAH). The approach involves creating dual agonist drugs, referred to as molecular artificial pancreas systems (mAPS), which aim to prevent dangerous low blood sugar episodes. By testing these novel drug candidates, the research seeks to improve glycemic control and reduce the risk of severe complications associated with diabetes. Patients participating in this research may receive a new treatment that could help them manage their condition more effectively.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of severe hypoglycemic episodes and related complications for patients with diabetes.
How similar studies have gone: Previous research has shown promise in developing treatments for hypoglycemia, but this specific approach using dual agonist insulins is novel.
Where this research is happening
-
Amidebio, LLC
Louisville, United States Active
Researchers
- Principal investigator: Fludzinski, Pawel — Amidebio, LLC
- Study coordinator: Fludzinski, Pawel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.